allopurinol sodium - Profile

What are the generic sources for allopurinol sodium and what is the scope of freedom to operate?

Allopurinol sodium is the generic ingredient in two branded drugs marketed by Gland, Hikma, and Mylan, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

Summary for allopurinol sodium

US Patents:	0
Tradenames:	2
Applicants:	3
NDAs:	3

US Patents and Regulatory Information for allopurinol sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gland	ALLOPURINOL SODIUM	allopurinol sodium	INJECTABLE;INJECTION	212363-001	Jan 26, 2022	AP	RX	No	No
Hikma	ALLOPURINOL SODIUM	allopurinol sodium	INJECTABLE;INJECTION	076870-001	Aug 26, 2004	AP	RX	No	No
Mylan	ALOPRIM	allopurinol sodium	INJECTABLE;INJECTION	020298-001	May 17, 1996	AP	RX	Yes	Yes

Investment Scenario and Fundamentals Analysis: Allopurinol Sodium (Allopurinol)

Last updated: April 23, 2026

Allopurinol sodium is an established small-molecule therapy for hyperuricemia and gout-related conditions. It is widely generic, concentrated in mature markets, and priced as a commodity drug. For investors, the fundamentals hinge less on clinical upside and more on (1) supply-chain execution, (2) regulatory and patent-ledge realities, (3) payer and tender dynamics, and (4) quality and manufacturing cost structure.

What is allopurinol sodium and what does it treat?

Allopurinol sodium is the sodium salt form used to deliver allopurinol activity. It is a xanthine oxidase inhibitor. The drug reduces uric acid formation and is used to manage:

• Chronic hyperuricemia in gout
• Prevention of gout flares in patients starting urate-lowering therapy
• Prevention and treatment of uric-acid-related complications (including in certain oncology settings where uric acid burden is expected)

Key mechanistic fact: as a xanthine oxidase inhibitor, allopurinol targets uric acid production rather than directly removing uric acid already present.

What is the demand profile and where does revenue come from?

Demand drivers (structural)

Allopurinol’s underlying demand is tied to:

• Prevalence of gout and chronic hyperuricemia in ageing populations
• Long-duration use patterns typical of urate-lowering therapy
• Ongoing clinician prescribing for first-line or long-established management pathways in many markets

Revenue mechanics (typical for generics)

For allopurinol sodium, revenue is mostly determined by:

• Share in tenders and formularies
• Manufacturing scale and cost per unit
• Ability to maintain supply and comply with pharmacopeial and regulatory quality expectations
• Contracting power versus other low-cost generics

Unlike branded launch stories, this market tends to reward operators who can produce at low cost and sustain quality throughput.

How competitive is the market and what does that mean for pricing?

Allopurinol is mature and heavily generic in most jurisdictions. That typically leads to:

• Rapid post-expiry price erosion
• Frequent interchangeability at the pharmacy and wholesaler level
• Margin compression across most manufacturers
• Competitive differentiation that shifts toward logistics, bioequivalence/CMC strength, and consistent availability

For investors, the base case is not growth via differentiation. It is market share retention and cost leadership.

What is the patent and exclusivity landscape risk profile?

For an established drug like allopurinol, investment returns are primarily shaped by:

• Whether any specific salt/formulation or new delivery method has a protectable position
• Whether local exclusivities exist around certain products, line extensions, or filings

At the molecule level, allopurinol has been off the original patent-led era for many years. In practice, investors should treat the market as primarily generic, with protection more likely to exist in:

• Specific product line dossiers
• Proprietary manufacturing processes (rarely monetized at the molecule level)
• Regulatory exclusivities for specific countries, if applicable to a particular filing

What are the formulation and CMC fundamentals that matter?

Even where the drug is generic, CMC performance drives commercial viability. The practical fundamentals for allopurinol sodium products include:

Manufacturing and quality control

• Stable handling of the sodium salt form and consistent solid-state quality
• Tight control of assay and impurities across batches
• Bioequivalence readiness for oral products and relevant dosage strengths (where applicable)
• Compliance with pharmacopeial standards and regulatory expectations for generics

Supply chain execution

• High-volume procurement and conversion economics for APIs and excipients
• Risk controls for API availability, lead times, and contingency sourcing
• Lot release and documentation discipline (batch traceability)

Operational cost structure

In commoditized segments, gross margin is often most sensitive to:

• API cost and contract terms
• Yield and throughput efficiency
• Batch rejection rates and rework costs

What does the regulatory path look like for investors?

For generic allopurinol sodium products, the investment pathway typically depends on:

• Regulatory strategy by jurisdiction (abbreviated pathways in most regions where permissible)
• Bioequivalence requirements for specific product formulations and strengths
• Product lifecycle management to prevent supply interruptions and maintain market standing

In markets where substitution is allowed and procurement uses tender-based purchasing, regulatory diligence directly influences commercialization timelines and repeat contract awards.

Where is the market concentrated and how does that affect competition?

Allopurinol’s demand sits across:

• Primary care and rheumatology prescribing patterns
• Chronic medication adherence ecosystems
• Pharmacy dispensing and tender procurement structures

Competition concentrates where wholesalers and tendering systems reward:

• Consistency of supply
• Price competitiveness
• Proven regulatory compliance

For investors, that means the “winning” model is not scientific differentiation. It is operational reliability plus low landed cost.

What is the likely investment thesis: what to underwrite and what to avoid

Underwrite

• Manufacturing scalability for a commodity urate-lowering drug
• Cost-down execution across API procurement, formulation scale, and packaging
• Regulatory and quality systems that prevent disruptions
• Commercial strength in tender-based and formulary-led channels

Avoid

• Overpaying for capacity that cannot compete on tender pricing
• Underestimating regulatory maintenance costs (repeat filings, variation work, inspections)
• Concentrating on a narrow product basket without a hedge against margin compression

Scenario analysis: outcomes by business model

1) Manufacturer-exporter (cost-led)

• Upside: share gains through low cost and reliable supply
• Base case: margin near generic benchmarks
• Downside: contract losses if price is forced down or supply problems occur

2) Regional generic marketer (tender-led)

• Upside: winning multi-year tenders can stabilize volume
• Base case: periodic price resets
• Downside: abrupt profitability hits when procurement recalibrates pricing

3) Specialty formulation entrant (if any product protection exists)

• Upside: narrow premium if a validated differentiation exists (e.g., specific formulation or delivery advantage)
• Base case: limited premium sustainability
• Downside: rapid generics interchangeability and price reversion

For allopurinol sodium, the most consistent historical investor logic is cost-led execution unless a specific, provable differentiation exists in a particular product dossier.

Investment fundamentals checklist (actionable for diligence)

Commercial

• Tender and formulary history in target geographies
• Customer concentration and contract duration patterns
• Dispensing substitution rules and procurement cost mechanisms

Regulatory and quality

• Abbreviated filing track record by jurisdiction
• Batch failure rate history, CAPA maturity, inspection outcomes
• Ongoing variation strategy for manufacturing changes

Financial and operational

• API cost pass-through capacity and hedging approach
• Yield and OEE for relevant dosage strengths
• Packaging and logistics capability for seasonal demand spikes

Risk controls

• Supplier redundancy for API and critical excipients
• Lot release timelines and historical lead times
• Insurance and recall readiness for high-volume products

What indicators should drive valuation in this drug segment?

In commoditized generics, valuation often responds most to:

• Evidence of sustained unit economics (margin stability after price resets)
• Volume durability under substitution and tender churn
• Inspection-grade quality outcomes and low supply disruption probability
• Manufacturing scale improvements that reduce COGS per unit

Key Takeaways

• Allopurinol sodium is a mature, commodity xanthine oxidase inhibitor used for chronic hyperuricemia and gout-related management.
• The investment case is primarily operational and commercial: tender and formulary execution, manufacturing cost and quality, and supply reliability.
• Patent upside is usually limited at the molecule level; differentiation, if any, tends to sit in specific product dossiers or process protections.
• Valuation should be anchored in unit economics resilience under recurring price pressure and in regulatory maintenance performance.

---

FAQs

1) Is allopurinol sodium a branded product or mainly generic?

It is predominantly generic in most markets, with broad substitution and price competition typical of mature small-molecule therapies.

2) What determines profitability most for allopurinol sodium producers?

COGS efficiency (API and manufacturing yield), quality execution, and the ability to win repeat tender contracts or retain formulary position despite frequent price resets.

3) What is the key clinical mechanism investors should recognize?

Allopurinol sodium is a xanthine oxidase inhibitor that lowers uric acid formation, supporting chronic management of hyperuricemia and gout.

4) Where are the main regulatory risks for generic allopurinol sodium?

Inspection outcomes, batch quality consistency, and timely management of CMC variations and maintenance requirements in each target jurisdiction.

5) What growth model fits this drug best?

Share gains through procurement relationships and cost leadership, rather than premium pricing based on clinical differentiation.

---

References

[1] FDA. “Allopurinol: Drug Approval Reports and labeling resources.” U.S. Food and Drug Administration. https://www.fda.gov/
[2] EMA. “European Public Assessment Reports (EPAR) and related information for allopurinol.” European Medicines Agency. https://www.ema.europa.eu/
[3] WHO. “ATC/DDD Index (Anatomical Therapeutic Chemical classification and defined daily doses) for allopurinol.” World Health Organization. https://www.whocc.no/